Literature DB >> 14637013

Priority setting in a hospital drug formulary: a qualitative case study and evaluation.

Douglas K Martin1, Daniel Hollenberg, Sue MacRae, Shannon Madden, Peter Singer.   

Abstract

Dramatically rising costs for new drugs are posing major challenges for hospital budgets. In response to these pressures, hospitals must set priorities for which drugs they will list on their formularies. While there have been studies relevant to decision making in hospitals regarding drugs, none have described how priority setting for drugs in hospitals is done and evaluated it against a framework of how it should be done. In this paper we describe the process of priority setting for new drugs in a hospital formulary and evaluate it using a leading conceptual framework for healthcare priority setting--Daniels and Sabin's 'accountability for reasonableness'. The findings from this study provide an evidence base for developing strategies to improve this hospital's priority setting regarding its drug formulary. The process we utilized here, describing using case study methods and evaluating using 'accountability for reasonableness', is a generalizable process for improving the fairness of priority setting in hospital drug formularies.

Keywords:  Empirical Approach; Professional Patient Relationship

Mesh:

Year:  2003        PMID: 14637013     DOI: 10.1016/s0168-8510(03)00063-0

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  17 in total

Review 1.  Setting Healthcare Priorities at the Macro and Meso Levels: A Framework for Evaluation.

Authors:  Edwine W Barasa; Sassy Molyneux; Mike English; Susan Cleary
Journal:  Int J Health Policy Manag       Date:  2015-09-16

Review 2.  Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels.

Authors:  Marieke E van Velden; Johan L Severens; Annoesjka Novak
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Hospital drug and therapeutics committees in Australia: is there a role for economic evaluation at the institutional level?

Authors:  Gisselle Gallego
Journal:  Int J Clin Pharm       Date:  2011-12

4.  Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework.

Authors:  Amani Thomas Mori; Eliangiringa Amos Kaale
Journal:  Implement Sci       Date:  2012-03-18       Impact factor: 7.327

5.  Evaluating priority setting success in healthcare: a pilot study.

Authors:  Shannon L Sibbald; Jennifer L Gibson; Peter A Singer; Ross Upshur; Douglas K Martin
Journal:  BMC Health Serv Res       Date:  2010-05-19       Impact factor: 2.655

6.  Principles versus procedures in making health care coverage decisions: addressing inevitable conflicts.

Authors:  Lindsay M Sabik; Reidar K Lie
Journal:  Theor Med Bioeth       Date:  2008-06-06

7.  Challenges to fair decision-making processes in the context of health care services: a qualitative assessment from Tanzania.

Authors:  Elizabeth H Shayo; Ole F Norheim; Leonard E G Mboera; Jens Byskov; Stephen Maluka; Peter Kamuzora; Astrid Blystad
Journal:  Int J Equity Health       Date:  2012-06-07

8.  Priority setting in developing countries health care institutions: the case of a Ugandan hospital.

Authors:  Lydia Kapiriri; Douglas K Martin
Journal:  BMC Health Serv Res       Date:  2006-10-06       Impact factor: 2.655

9.  The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees.

Authors:  Mikael Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

10.  What do district health planners in Tanzania think about improving priority setting using 'Accountability for reasonableness'?

Authors:  Simon Mshana; Haji Shemilu; Benedict Ndawi; Roman Momburi; Oystein Evjen Olsen; Jens Byskov; Douglas K Martin
Journal:  BMC Health Serv Res       Date:  2007-11-12       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.